ELSEVIER

Pharmacology Biochemistry and Behavior, Vol. 61, No. 4, pp. 473, 1998
© 1998 Elsevier Science Inc.
Printed in the USA. All rights reserved
0091-3057/98 $19.00 + .00

VOLUME 61, 1998
AUTHOR INDEX

Aberman, J.E., 341
Aguilar-Bravo, H., 1
Akiyama, K., 419
Anderson, K.G., 207
Angeletti, S., 459
Ardenghi, P., 239

Baird, T.J., 303
Baker, D.A., 107
Balster, R.L., 271
Barrett, R.J., 323
Barringer, T.M., 181
Bartolomé, S., 229
Bedingfield, J.B., 291, 435
Bettegowda, C., 335
Beyer, C., 45
Bhargava, H.N., 29
Bian, J.-T., 29
Blundell, J.E., 159
Bowen, S.E., 271
Boyer, J.S., 395
Briscoe, R.J., 303
Brotto, L.A., 405

Caba, M., 45
Calder, L.D., 435
Canton, H., 323
Carper, R., 113
Castañeda, E., 35
Castejón, A.M., 451
Cavallaro, C.A., 181
Chavarria, M.E., 445
Chimirri, A., 215
Christopher, N.C., 335
Ciccocioppo, R., 459
Cierpial, M.A., 49
Craft, R.M., 395
Crow, S., 317
Cubeddu, L.X., 451

De Sarro, A., 215
De Sarro, G., 215
Del Arco, I., 229
Díaz-Véliz, G., 221
Dussaubat, N., 221
Duvauchelle, C.L., 297

Edamura, K., 175
Estupinan, L.E., 375
Etou, K., 427

Faraday, M.M., 281
Feng, C., 349
France, C.P., 375
Friedman, S.D., 35
Froldi, R., 459

Gabryszuk, M., 169
Gauvin, D.V., 303
Gerak, L.R., 375
Gerstein, A.V., 19
Getty, M.E., 9
Gitto, R., 215
Glennon, R.A., 169
Gorzalka, B.B., 405
Grunberg, N.E., 281, 413
Gudelsky, G.A., 361
Guo, A., 349

Halford, J.C.G., 159
Hanesworth, J.M., 395
Hanson, L.A., 405
Harding, J.W., 395
Hart, S., 113
Hodge, G.K., 35
Holloway, F.A., 291, 303
Holtman, J.R., 121
Hubbell, C.L., 181

Ikemoto, S., 87
Izquierdo, I., 239

Jing, X., 121
Joseph, M.M., 193
Joshi, A., 331

Kalynchuk, L.E., 143
Kameyama, T., 247
Kanarek, R.B., 19
Karler, R., 435
Kawahara, T., 427
King, D.A., 291
Kippin, T.E., 143
Klein, L.C., 413
Kobayashi, T., 381
Kodama, M., 419
Komisaruk, B.R., 45
Kornecook, T.J., 143
Kornetsky, C., 297
Kruzich, P.J., 395
Kuroda, S., 419
Kuroki, T., 427

Larson, S.J., 131
Levin, E.D., 335
Li, M., 93
Liu, L., 349
Lopez-Mendoza, D., 1
Lyons, D., 201

Macenski, M.J., 367
Maeda, H., 247
Mallick, B.N., 193
Marder, M., 239
Martín-Calderón, J.L., 229
Massi, M., 459
Matsuno, K., 247, 381
McBride, W.J., 87
McMillan, D.E., 93
McNally, G.P., 385
Medina, J.H., 239
Meisch, R.A., 367
Meller, W., 317
Mendelson, W.B., 81
Mendez, J.J., 181
Milliken, B., 121
Miranda, H.F., 357
Mitchell, J., 317
Mito, S., 381
Mora, S., 221
Murphy, J.M., 87

Nanya, Y., 247
Navarro, M., 229
Neisewander, J.L., 107

Pabello, N.G., 181
Paladini, A., 239
Panocka, I., 459
Parker, L.A., 331
Pinardi, G., 357
Pinel, J.J.P., 143
Polidori, C., 459
Popke, E.J., 413
Porrino, L.J., 201
Praus, B., 317

Raatz, S., 317
Rahman, M.A., 281
Reid, L.D., 181
Reyes, A., 445
Rizzo, M., 215
Rodríguez de Fonseca, F., 229
Rodriguez-Medina, M.A., 445
Rosada, A., 445
Rubio, P., 229
Rush, C.R., 253
Rúveda, E., 239

Sakai, K., 419
Salamone, J.D., 341
Sanders-Bush, E., 323
Sapoznik, T., 297
Sasai, H., 175
Scheufele, P.M., 281
Schröder, N., 239
Schrott, L.M., 9
Shankaran, M., 361
Shelton, K.L., 367
Shimizu, Y., 419
Siegel, S., 131
Sinopoli, V.A., 215
Sloan, J.W., 121
Smith, R.L., 323
Sparber, S.B., 9
Specio, S.E., 107
Swanson, H.H., 1
Swerdlow, N.R., 113

Tashiro, N., 427
Thai, D.K., 435
Tran-Nguyen, L.T.L., 107

Uchimura, H., 427
Ujike, H., 419
Ukai, M., 247

Vallett, M., 303
van Haaren, F., 207
Vanecek, S.A., 303
Vergara, M., 445
Villanúa, M.A., 229
Viola, H., 239

Wacnik, P.W., 9
Wala, E., 121
Wang, X., 349
Wanninayake, S.C.D., 159
Ward, S.J., 341
Wasowski, C., 239
Weaver, T., 335
Weiss, J.M., 49, 67
West, C.H.K., 49, 67
Westbrook, R.F., 385
Whitlow, C.T., 201
Wolfman, C., 239

Xia, S., 349

Yonezawa, Y., 427
Young, R., 169

Zappala, M., 215
Zreik, M., 113

ELSEVIER

Pharmacology Biochemistry and Behavior, Vol. 61, No. 4, pp. 475–476, 1998
© 1998 Elsevier Science Inc.
Printed in the USA. All rights reserved
0091-3057/98 $19.00 + .00

VOLUME 61, 1998
KEYWORD INDEX

Abuse potential, 253
Acoustic startle reflex, 281
ACTH, 229
Activity, 19
Acute dependence, 331
Addivity, 291
Adrenergic, 193
α-Adrenergic system, 317
Aggression, 1
Agonist, 239, 323
Agonist-antagonist, 193
Alcohol, 201
Alcohol, ethyl, 143
Alcohol intake, 459
Alcohol-preferring rats, 459
Alcohol tolerance, 131
Aminosenktide, 459
AMPA/kainate antagonists, 215
AMPA receptors, 419
Amphetamine, 107, 169, 435
Amygdaloid body, 143
Analgesia, 19, 45
Animal models, 67
Animal models of depression, 49
Anticonvulsants, 143
Antidepressants, 67, 247
Antinociception, 29, 357
Antipsychotics, 113
Anxiety, 239, 451
Apomorphine, 113
APRT, 175
Ataxia, 131
Atypical depression, 67
Autoradiography, 201
Avoidance conditioning, 221
Avoidance of time-out, 207
Avoidance response, 207

Behavior, 323
Behavioral economics, 341
Behavioral history, 93
Behavioral impairment, 35
Behavioral satiety sequence, 159
Behavioral sensitization, 419
Benzaldehyde, 349
2,3-Benzodiazepine, 215
Benzodiazepine antagonists, 121
Benzodiazepine receptors, 239
Benzodiazepines, 81, 253, 451
Body temperature, 303
Body weight, 19
Brain regions, 29
Brain stimulation reward, 181
Break point, 297
Buspirone, 93, 207, 451

Caffeine, 169, 291
Calmodulin concentraiton, 445
cAMP, 349
Cannabinoids, 229
Caudal linear nucleus, 87
β-CCE, 375
β-CCM, 375
Central benzodiazepine receptors, 121
Ceruletide, 427
Chlordiazepoxide, 207
Cholecystokinin, 427
Cholinergic, 193, 335
Chronopharmacology, 303
Circadian rhythm, 303
Clonidine, 317
Cocaine, 9, 93, 181, 291, 419, 435
Cocaine abuse, 181
Cocaine dependence, 181
Cocaine treatment, 181
Cocaine use disorders, 181
Conditioned place preference, 107, 291
Conditioning, 131, 229
Conflict test, 451
Continuous observation, 159
Convulsions, 143
Cortex, 435
Corticosterone, 229
Cosinor analysis, 303

Dependence, 253
Depression, 67
Desipramine hydrochloride (DMI), 49
Diazepam, 93, 143, 375
1-(3,4-Dimethyoxyphenyl)-4-(3-phenylpropyl) piperazine dihydrochloride, 381
N,N-Dimethyltryptamine, 323
Discrimination, 395
Diuresis, 395
Dizocilpine, 335, 427
Dopamine, 113, 159, 361, 427, 435
Drosophila melanogaster, 349
Drug abuse, 169
Drug combination, 367
Drug discrimination, 93, 253, 323
Drug self-administration, 297
Drugs, 67, 143

EEG, 121
Endogenous opioid peptides, 413
Ephedrine, 169
Epilepsy, 215
Estradiol, 221
Estrogen, 405
Estrous cycle, 221
Ethanol, 303, 367
Ethanol tolerance, 131
9-Ethyladenine, 175
Exercise, 19
External inhibition, 131

Feeding behavior, 317
Female, 19
d-Fenfluramine, 159
Flavonoids, 239
Flight orientation, 349
Flumazenil, 121
Fluoxetine, 159, 181
Focal injection, 121
Food intake, 159
Food restriction, 19
Footshock, 413
Freezing, 413
Functional activity, 201

GABA, 435
$GABA_A$ receptors, 87
Gallus domesticus, 9
Genetically epilepsy prone rats, 215
Gepirone, 1
Glutamate, 45
Glutaminergic, 335
Glycine receptors, 45

Hallucinogen, 323
Haloperidol, 113
Hangover, 303
Herbal dietary supplements, 169
Hippocampus, 121, 361
Hippocampus CA1, 121
Housing conditions, 281
HPRT-deficient mouse, 175
5-HT_3 receptors, 451
5-HT_{2A} receptors, 405
Humans, 253
Hyperalgesic properties, 385
Hypnotics, 253
Hypothalamus, 81, 445

Imidazopyridines, 253
In vivo microdialysis, 427
Inhalant abuse, 271
Interaction, 193
Intracranial self-administration, 87
Intrathecal, 45
Isoparaffins, 271
Isradipine, 181

Kindling (neurology), 143

Learning, 331
Lesch-Nyhan Syndrome, 175
Lever press, 207
LHRH, 221
Liability, 253
Lipopolysaccharide, 9
Lithium chloride-induced hyperalgesia, 385
Locomotion, 107, 159
Locomotor activity, 271, 291, 303
Long-Evans, 19
Long-Evans rats, 281
Long-term monoamine depletion, 35

MDMA, 361
Medial preoptic area, 81
Medial preoptico-anterior hypothalamic area, 193
Memory, 335
Memory impairment, 253
Methadone, 367
Methamphetamine, 93, 419
Methamphetamine-induced neurotoxicity, 35
Mice, 1, 247, 435
Morphine, 19, 29, 93, 229, 331, 357
Morphine concentraiton, 29
Motivation, 341
Motor activity, 49
Motor effects, 435
Motor responses, 221
Movement, 341
Muscimol, 87

Naloxone, 331, 357, 413
Naltrexone, 181
NBQX, 419
Negative $GABA_A$ modulators, 375
Negative reinforcement, 207
Nicotine, 281, 335
Nicotinic, 335
Nitric oxide, 29
NMDA, 335
NMDA receptor, 45
Nociception, 45

Obesity drugs, 159
Ondansetron, 451
Open field, 9, 67
Operant, 341
Operant behavior, 271
Operant conditioning, 349
Opioids, 19, 395
Opioids motor effects, 297
Oral stereotypies, 107
Osmotic minipumps, 49
Ovariectomy, 221

Pain, 19, 45
Performance impairment, 253
Perinatal exposure, 229
Peripheral benzodiazepine receptors, 121
Peripheral tissues, 29
Pharmacokinetics, 201
Phase shift, 303
Phencyclidine, 93, 427
Pigeons, 93
PK 11195, 121
Place aversion, 331
Place conditioning, 331, 459
Plasma level, 215
Polydrug abuse, 367
Precipitated withdrawal, 331
Prefrontal cortex, 427
Prepulse , 113
Prepulse inhibition, 281
Progesterone, 405
Progressive ratio, 341
Psychostimulants, 297
Punishment, 93

Radial-arm maze, 335
Random-time schedule, 207
Rat model, 67
Rats, 143, 207, 229, 297, 331, 427
Receptor, 323
σ Receptor agonist, 247
σ_1 Receptor subtype, 247
Reference memory, 335
Reinforcement, 87, 229, 341
Release, 427
Repeated administration, 247
Resident/intruder, 1
Resting, 159
Reward, 107, 297, 341
Rhesus monkeys, 367, 375
Ritanserin, 9
Ro 15-4513, 375
Running wheels, 19

SA4503, 247, 381
Satiety, 317
Schizophrenia, 113
Sedation, 239
Selective bleeding, 49
Self-administration, 253, 367
Self-injurious behavior, 175
Sensitization, 435
Sensorimotor, 113
Serotonin, 323, 361, 405, 427, 451
Serotonin (5-HT), 159
Session duration, 297
Sex differences, 395, 413
Sexual behavior, 405
Sexual differentiation, 445
Sibutramine, 159
Sickness behavior, 9
$Sigma_1$ receptor agonist, 381
$Sigma_1$ receptor subtype, 381
Sleep-wakefulness, 193
Solvents, 271
Spinal cord, 45
Startle, 113
Sterotyped behaviors, 381
Stimulants, 169
Strain differences, 281
Stress, 405, 413
Striatum, 427
Subjective effects, 253
SwHi/SwLo rats, 49
Swim test, 49, 67

Tachykinin NK-3 receptors, 459
Tail-flick test, 19, 385
Tail-suspension test, 247
Tamoxifen treatment, 445
Testosterone treatment, 445
Thermoregulation, 193
Time-in, 207
Time-out, 207
Tolerance, 19, 143
Tolerance physical dependence, 357
Toxicology, 271
Tramadol, 357
Triazolam, 81

U69,593, 395

Vaginal stimulation, 45
Ventilation, 375
Ventral tegmental area, 87
Ventrolateral striatum, 107
Visual associative learning, 349

(+)WAY 100135, 1
Wet dog shakes, 405
Withdrawal, 121, 331
Working memory, 335

Zolpidem, 253